First interim results on treatment satisfaction and pharmaco-economic data comparing Fingolimod and first-line therapies in multiple sclerosis patients in Germany (PANGAEA and PEARL)

被引：0
|
作者：
Ortler, Sonja [1 ]
Ziemssen, Tjalf [2 ]
Antonius, van Lokven [1 ]
Meergans, Matthias [1 ]
机构：
[1] Pharma GmbH, Novartis, Nurnberg, Germany
[2] Klinikum Karl Gustav Carus, Klin & Poliklin Neurol, Dresden, Germany
来源：
JOURNAL OF NEUROIMMUNOLOGY | 2012年 / 253卷 / 1-2期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：31 / 32
页数：2
相关论文
共 50 条
  • [1] Interim Results of the PANGAEA and PEARL Studies, Comparing Treatment Satisfaction and Pharmaco-Economic Data of Fingolimod (Gilenya®) and First-Line Therapies in Multiple Sclerosis Patients in Germany
    Ziemssen, Tjalf
    Vollmar, Patrick
    Meergans, Matthias
    Tracik, Ferenc Mark
    Lorente, Maria Diaz
    Neidhardt, Katja
    van Lokven, Tom
    NEUROLOGY, 2013, 80
  • [2] First interim results on treatment satisfaction and pharmacoeconomic data comparing fingolimod and first-line therapies in multiple sclerosis patients in Germany (PANGAEA and PEARL)
    Ortler, S.
    Ziemssen, T.
    Meergans, M.
    Tracik, F.
    van Lokven, A.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 113 - 113
  • [3] Study design and first interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)
    Ziemssen, T.
    Meergans, M.
    Vollmar, P.
    Kempcke, R.
    Tracik, F.
    van Lokven, T.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 222 - 223
  • [4] 18-Month Interim Results of a Registry Study To Establish Long-Term Safety and Pharmaco-Economic Data on Fingolimod (Gilenya®) in Multiple Sclerosis Patients in Germany (PANGAEA)
    Ziemssen, Tjalf
    Lorente, Maria Diaz
    Vollmar, Patrick
    Meergans, Matthias
    Tracik, Ferenc Mark
    Kempcke, Raimar
    van Lokven, Tom
    NEUROLOGY, 2013, 80
  • [5] 18-month interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)
    Ziemssen, T.
    Vollmar, P.
    Diaz-Lorente, M.
    Fuchs, A.
    van Lokven, T.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 318 - 318
  • [6] Study design and first results of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)
    Ziemssen, T.
    van Lokven, T.
    Kempcke, R.
    Meergans, M.
    JOURNAL OF NEUROLOGY, 2012, 259 : S72 - S72
  • [7] Study Design and First Results of a Non-Interventional Registry Study To Establish Long-Term Safety and Pharmaco-Economic Data on Fingolimod (Gilenya®) in Multiple Sclerosis Patients in Germany (PANGAEA)
    Ziemssen, Tjalf
    van Lokven, Tom
    Kempke, Raimar
    Meergans, Matthias
    NEUROLOGY, 2012, 78
  • [8] Changes in current Evaluation of new Drugs needs Survey of pharma-economic Data: Treatment Satisfaction of Fingolimod (Gilenya) in Comparison to First-Line-Therapeutics in Multiple Sclerosis Patients (PANGAEA and PEARL)
    Ziemssen, Tjalf
    van Lokven, Tom
    Ortler, Sonja
    Meergans, Matthias
    AKTUELLE NEUROLOGIE, 2012, 39 (07) : 385 - 385
  • [9] The effect of natalizumab, fingolimod and first-line treatment on brain atrophy in patients with multiple sclerosis
    Noteboom, S.
    Strijbis, E. M. M.
    Coerver, E. M. E.
    van Kempen, Z. L. E.
    Killestein, J.
    Barkhof, F.
    Vrenken, H.
    Steenwijk, M. D.
    Schoonheim, M. M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 269 - 270
  • [10] Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)
    van Lokven, T.
    Kempcke, R.
    Ziemssen, T.
    Meergans, M.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S213 - S214
12345